Small-cell carcinoma in the setting of pulmonary adenocarcinoma: New insights in the era of molecular pathology

Journal of Thoracic Oncology

Volumn 8, Issue 10, 2013, Pages 1265-1271

  Norkowski, Emma ^a   Ghigna, Maria Rosa ^a   Lacroix, Ludovic ^b   Le Chevalier, Thierry ^b   Fadel, Élie ^a   Dartevelle, Philippe ^a   Dorfmuller, Peter ^a   De Montpréville, Vincent Thomas ^a  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Combined small cell carcinoma; Epidermal growth factor receptor mutation; Molecular pathology; Pathology; Pulmonary adenocarcinoma

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; TOPOTECAN;

ADULT; AGED; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; DEATH; DISEASE ASSOCIATION; DISEASE DURATION; EXON; FEMALE; FRANCE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LYMPH NODE DISSECTION; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA;

EID: 84892411513     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182a407fa     Document Type: Article

References (32)

1. Pao W, Miller VA. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
4. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
5. Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006;17:1028-1029.
6. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in smallcell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-215.
7. Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of nonsmall cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007;58:411-413.
8. Alam N, Gustafson KS, Ladanyi M, et al. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 2010;11:E1-E4.
9. Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O'Brien M. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;80:1-4.
10. Ma AT, Chan WK, Ma ES, Cheng T, Cheng PN. Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinibresistant adenocarcinoma of the lung. Acta Oncol 2012;51:557-559.
11. van Riel S, Thunnissen E, Heideman D, Smit EF, Biesma B. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. Ann Oncol 2012;23:3188-3189.
12. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
13. Shiao TH, Chang YL, Yu CJ, et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 2011;6:195-198.
14. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008;14:6092-6096.
15. Lu HY, Sun WY, Chen B, et al. Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China. Neoplasma 2012;59:100-104.
16. Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Hum Pathol 1992;23:520-528.
17. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol 1989;7:607-612.
18. Deslauriers J. Surgery for small cell lung cancer. Lung Cancer 1997;17 Suppl 1:S91-S98.
19. Lucchi M, Mussi A, Chella A, et al. Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 1997;12:689-693.
20. Hage R, Elbers JR, Brutel de la Rivière A, van den Bosch JM. Surgery for combined type small cell lung carcinoma. Thorax 1998;53:450-453.
21. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-1197.
22. de Antonio DG, Alfageme F, Gámez P, Córdoba M, Varela A; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Results of surgery in small cell carcinoma of the lung. Lung Cancer 2006;52:299-304.
23. Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 2007;98:1714-1719.
24. Lu HY, Mao WM, Cheng QY, et al. Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncol Lett 2012;3:1288-1292.
25. Travis WD, Brambilla E, Müller-Hermelink HK, et al. World Health Organisation Classification of Tumour; Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press, 2004.
26. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
27. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
28. Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki J. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 2005;48:141-144.
29. Kurahara Y, Kawaguchi T, Tachibana K, et al. Small-cell lung cancer in never-smokers: a case series with information on family history of cancer and environmental tobacco smoke. Clin Lung Cancer 2012;13:75-79.
30. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-1110.
31. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
32. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111-116.